Tokyo Tape
Sign in
← I'rom Group

Half-year report · Q2

2372.TEDINET S100UMR9
Period2024-04-01 → 2024-09-30
Filed2024-11-06
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥8.8bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥17.7bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥8.7bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥85m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥790m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥75m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥1.8bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.2bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥52m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥1.4bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥65m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.4bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥65m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥1.1bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥35.3bnat 2024-09-30Cons.Assets
Total assets¥37.1bnat 2024-03-31Cons.Assets
Total assets¥36.2bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥22.7bnat 2024-09-30Cons.Liabilities
Total liabilities¥24.4bnat 2024-03-31Cons.Liabilities
Net assets / equity¥12.6bnat 2024-09-30Cons.Net assets
Net assets / equity¥12.8bnat 2024-03-31Cons.Net assets
Net assets / equity¥13.0bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥7.3bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥7.2bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥7.3bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥7.2bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥8.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥9.4bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.3bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥446m2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥803m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥280m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥1.5bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥163m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥17m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-5.412024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥116.922023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥90.222023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio35.8%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.4%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio35.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 63
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2024-09-30¥4m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2024-09-30¥4m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2024-09-30−¥95m
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥1.8bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥969m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue2024-04-01 → 2024-09-30¥1.2bn
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue external2024-04-01 → 2024-09-30¥597m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥554m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentsegment profit2024-04-01 → 2024-09-30−¥101m
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue2024-04-01 → 2024-09-30¥3.8bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue external2024-04-01 → 2024-09-30¥3.4bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥344m
jpcrp040300-q2r_E05352-000CROreportable segmentsegment profit2024-04-01 → 2024-09-30−¥41m
jpcrp040300-q2r_E05352-000Drug Discovery Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥229m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue2024-04-01 → 2024-09-30¥1.1bn
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue external2024-04-01 → 2024-09-30¥506m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥626m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentsegment profit2024-04-01 → 2024-09-30¥95m
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue2024-04-01 → 2024-09-30¥4.6bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue external2024-04-01 → 2024-09-30¥4.3bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥320m
jpcrp040300-q2r_E05352-000SMOreportable segmentsegment profit2024-04-01 → 2024-09-30¥1.4bn
—segment totalrevenue2024-04-01 → 2024-09-30¥10.7bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥8.8bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥1.8bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥1.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥10.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥8.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥1.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥1.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥250m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥219m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥31m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥25m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥2.4bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥2.4bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥913m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue2023-04-01 → 2023-09-30¥1.8bn
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue external2023-04-01 → 2023-09-30¥884m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥887m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentsegment profit2023-04-01 → 2023-09-30−¥20m
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue2023-04-01 → 2023-09-30¥3.4bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue external2023-04-01 → 2023-09-30¥2.8bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥610m
jpcrp040300-q2r_E05352-000CROreportable segmentsegment profit2023-04-01 → 2023-09-30¥66m
jpcrp040300-q2r_E05352-000Drug Discovery Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥367m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue2023-04-01 → 2023-09-30¥903m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue external2023-04-01 → 2023-09-30¥494m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥409m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentsegment profit2023-04-01 → 2023-09-30−¥39m
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue2023-04-01 → 2023-09-30¥4.8bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue external2023-04-01 → 2023-09-30¥4.3bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥490m
jpcrp040300-q2r_E05352-000SMOreportable segmentsegment profit2023-04-01 → 2023-09-30¥2.1bn
—segment totalrevenue2023-04-01 → 2023-09-30¥10.9bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥8.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥2.4bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥1.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥11.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥8.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥2.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥1.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 551
ItemContextValueUnit
Directors compensations sgaCurrentYTDDuration256000000JPY
Salaries allowances and bonuses sgaPrior1YTDDuration1214000000JPY
Salaries allowances and bonuses sgaCurrentYTDDuration1441000000JPY
Rent expenses sgaPrior1YTDDuration241000000JPY
Rent expenses sgaCurrentYTDDuration368000000JPY
Research and development expenses sgaPrior1YTDDuration242000000JPY
Research and development expenses sgaCurrentYTDDuration137000000JPY
Other sgaPrior1YTDDuration1073000000JPY
Other sgaCurrentYTDDuration1112000000JPY
Selling general and administrative expensesPrior1YTDDuration3025000000JPY
Selling general and administrative expensesCurrentYTDDuration3316000000JPY
Operating incomePrior1YTDDuration790000000JPY
Operating incomeCurrentYTDDuration85000000JPY
Interest income noiPrior1YTDDuration8000000JPY
Interest income noiCurrentYTDDuration18000000JPY
Dividends income noiPrior1YTDDuration0JPY
Dividends income noiCurrentYTDDuration0JPY
Foreign exchange gains noiPrior1YTDDuration511000000JPY
Foreign exchange gains noiCurrentYTDDuration－JPY
Gain on investment of securities noiPrior1YTDDuration－JPY
Gain on investment of securities noiCurrentYTDDuration80000000JPY
Rent income noiPrior1YTDDuration107000000JPY
Rent income noiCurrentYTDDuration149000000JPY
Other noiPrior1YTDDuration69000000JPY
Other noiCurrentYTDDuration105000000JPY
Non operating incomePrior1YTDDuration697000000JPY
Non operating incomeCurrentYTDDuration355000000JPY
Interest expenses noePrior1YTDDuration85000000JPY
Interest expenses noeCurrentYTDDuration103000000JPY
Foreign exchange losses noePrior1YTDDuration－JPY
Foreign exchange losses noeCurrentYTDDuration188000000JPY
Loss on investment of securities noePrior1YTDDuration56000000JPY
Loss on investment of securities noeCurrentYTDDuration－JPY
Cost of lease revenue noePrior1YTDDuration91000000JPY
Cost of lease revenue noeCurrentYTDDuration158000000JPY
Other noePrior1YTDDuration29000000JPY
Other noeCurrentYTDDuration66000000JPY
Non operating expensesPrior1YTDDuration263000000JPY
Non operating expensesCurrentYTDDuration516000000JPY
Ordinary incomePrior1YTDDuration1225000000JPY
Ordinary incomeCurrentYTDDuration-75000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration193000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration128000000JPY
Extraordinary incomePrior1YTDDuration193000000JPY
Extraordinary incomeCurrentYTDDuration128000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration3000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration0JPY
Extraordinary lossPrior1YTDDuration3000000JPY
Extraordinary lossCurrentYTDDuration0JPY
Income before income taxesPrior1YTDDuration1414000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass